ESR1 and breast carcinoma: To take more appropriate treatments in the clinic for breast cancer patients, several computational/non-computational studies have been conducted to improve prognostic staging systems through assessment of biomarkers, including estrogen receptor status (ER) and human epidermal growth factor receptor 2 status (HER2) for breast cancer patients, or using the predictive recurrence models, such as Oncotype DX [2–4].